Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
- PMID: 15548812
- PMCID: PMC1772424
- DOI: 10.1136/bjo.2003.039552
Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Abstract
Aim: To evaluate factors influencing change in visual acuity (VA) after intravitreal injection of triamcinolone acetonide as treatment of exudative age related macular degeneration (AMD).
Methods: This prospective, interventional, comparative non-randomised clinical case series study included 94 patients (99 eyes) showing progressive exudative AMD with occult (n = 61 eyes), minimally classic (n = 18), predominantly classic (n = 1), or totally classic (n = 8) subfoveal neovascularisation. Mean follow up was 8.5 (SD 4.7) months (median, 7.3 months; range 3.1-24.5 months). All patients received an intravitreal injection of 20-25 mg of triamcinolone acetonide.
Results: An increase in best VA of at least one line on the Snellen charts was found in 63 (63.1%) eyes. Correspondingly, mean VA increased significantly (p<0.001) from 0.17 (SD 0.13) to 0.22 (SD 0.17) after the injection. Postoperative increase in VA was significantly (p<0.001) and negatively correlated with preoperative VA (correlation coefficient, -0.49). Gain in visual acuity was significantly (p = 0.009) higher if preoperative visual acuity was less than 0.08 (gain: 3.2 (SD 2.9) Snellen lines) than if preoperative VA ranged between 0.08 and 0.20 (gain: 1.2 (SD 2.2) Snellen lines). Change in VA was significantly (p = 0.016) less if preoperative VA was higher than 0.20 (change: -0.8 (SD 3.4) Snellen lines). Maximal gain in VA was significantly (p = 0.035) larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation. This was statistically independent of age (p = 0.99), refractive error (p = 0.88), sex (p = 0.92), and duration of follow up (p = 0.46).
Conclusions: Gain in VA after intravitreal injection of 20-25 mg of triamcinolone acetonide is significantly and negatively correlated with preoperative VA. It is significantly larger in eyes with retinal pigment epithelium detachment than in eyes with minimally classic subfoveal neovascularisation.
Figures




Similar articles
-
Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.Am J Ophthalmol. 2005 Jun;139(6):1073-9. doi: 10.1016/j.ajo.2005.01.032. Am J Ophthalmol. 2005. PMID: 15953439 Clinical Trial.
-
Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.Acta Ophthalmol Scand. 2007 Aug;85(5):563-5. doi: 10.1111/j.1600-0420.2007.00891.x. Epub 2007 Feb 27. Acta Ophthalmol Scand. 2007. PMID: 17324219
-
Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration.J Ocul Pharmacol Ther. 2006 Oct;22(5):370-6. doi: 10.1089/jop.2006.22.370. J Ocul Pharmacol Ther. 2006. PMID: 17076632 Clinical Trial.
-
[Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].Klin Monbl Augenheilkd. 2003 Jun;220(6):384-90. doi: 10.1055/s-2003-40272. Klin Monbl Augenheilkd. 2003. PMID: 12830391 Review. German.
-
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.Acta Ophthalmol Scand. 2005 Dec;83(6):645-63. doi: 10.1111/j.1600-0420.2005.00592.x. Acta Ophthalmol Scand. 2005. PMID: 16396641 Review.
Cited by
-
Clearance of autophagy-associated dying retinal pigment epithelial cells - a possible source for inflammation in age-related macular degeneration.Cell Death Dis. 2016 Sep 8;7(9):e2367. doi: 10.1038/cddis.2016.133. Cell Death Dis. 2016. PMID: 27607582 Free PMC article.
-
Expression and functional roles of caspase-5 in inflammatory responses of human retinal pigment epithelial cells.Invest Ophthalmol Vis Sci. 2011 Nov 7;52(12):8646-56. doi: 10.1167/iovs.11-7570. Invest Ophthalmol Vis Sci. 2011. PMID: 21969293 Free PMC article.
-
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium-Role in Dead Cell Clearance and Inflammation.Int J Mol Sci. 2019 Feb 20;20(4):926. doi: 10.3390/ijms20040926. Int J Mol Sci. 2019. PMID: 30791639 Free PMC article.
-
Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.Br J Ophthalmol. 2007 Feb;91(2):174-9. doi: 10.1136/bjo.2006.103606. Epub 2006 Sep 20. Br J Ophthalmol. 2007. PMID: 16987898 Free PMC article. Clinical Trial.
-
The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.Eye (Lond). 2011 Feb;25(2):127-39. doi: 10.1038/eye.2010.196. Epub 2010 Dec 24. Eye (Lond). 2011. PMID: 21183941 Free PMC article.
References
-
- Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001;132:425–7. - PubMed
-
- Martidis A , Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920–7. - PubMed
-
- Jonas JB, Kreissig I, Söfker A, et al. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2003;121:57–61. - PubMed
-
- Jonas JB, Hayler JK, Söfker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468–71. - PubMed
-
- Jonas JB, Hayler JK, Söfker A, et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001;10:284–7. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical